Please login to the form below

Not currently logged in
Email:
Password:

Stemcentrx

This page shows the latest Stemcentrx news and features for those working in and with pharma, biotech and healthcare.

Bluebird and Celgene BCMA CAR-T kicks off ASCO

Bluebird and Celgene BCMA CAR-T kicks off ASCO

ADCs on show include Pfizer and AbbVie’s cofetuzumab pelidotin, a PTK7-targeting drug that was picked up by the latter via its 2-16 purchase of Stemcentrx, though that deal

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Stemcentrx represents a good fit with AbbVie's oncology portfolio and is forecast to generate multibillion $revenue. ... Not content with the Stemcentrx acquisition, in April AbbVie also closed two other oncology deals:.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics